Tin tức & Cập nhật

Outpatient initiation of venetoclax safe, feasible in acute myeloid leukaemia
Outpatient initiation of venetoclax safe, feasible in acute myeloid leukaemia
24 Nov 2023

Initiation of venetoclax for acute myeloid leukaemia (AML) in the outpatient setting with a pharmacist-led interdisciplinary protocol is both feasible and safe, reports a study.

Outpatient initiation of venetoclax safe, feasible in acute myeloid leukaemia
24 Nov 2023
Is nintedanib safe, effective in patients with early-stage IPF?
Is nintedanib safe, effective in patients with early-stage IPF?
24 Nov 2023 bởiStephen Padilla

Results of nintedanib use in patients with early-stage idiopathic pulmonary fibrosis (IPF) show a stable change in forced vital capacity (FVC) and a gradual decline in diffusing capacity of the lungs for carbon monoxide (DLCO) at week 52, according to an ongoing study presented at APSR 2023. In addition, treatment discontinuation is comparable to that in previous clinical trials.

Is nintedanib safe, effective in patients with early-stage IPF?
24 Nov 2023
Novel tri-agonist confers significant gains for MASLD patients
Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023 bởiAudrey Abella

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.

Novel tri-agonist confers significant gains for MASLD patients
24 Nov 2023